Ann: Clarity strengthens Cu-64 network with new supply agreement, page-47

When I mentioned “it depends on the individual patient’s treatment regime” I’m talking about Cu67 as a treatment because there is still a lot of data to be obtained for different cancers.
As far as how many oncologist would prefer to use Cu64 as the diagnosis tool of choice. On available data so far, I’d say 100% would use Cu64. What’s the point in planning a patient for radiation therapy treatment when you don’t have as much certainty whether metastasis exists. Cu64 is proving to be a far greater diagnosis tool than gallium.It’s a no brainer.
I don’t know what type of clinician you are talking about but it’s the Radiation Oncologist that calls the shots with a patient’s radiation treatments not a radiologist.